98%
921
2 minutes
20
Unlabelled: Background: The white blood cell count to mean platelet volume ratio (WMR) is increasingly gaining importance as a promising prognostic marker in atherosclerotic disease, but data on lower extremity artery disease (LEAD) are not yet available. The principle aim of this study was to assess the association of the WMR with the occurrence of CLTI (chronic limb-threatening ischemia) as the most advanced stage of disease.
Methods: This study was performed as a retrospective analysis on 2121 patients with a diagnosis of LEAD. Patients were admitted to the hospital for the reason of LEAD and received conservative or endovascular treatment. Blood sampling, in order to obtain the required values for this analysis, was implemented at admission. Statistical analysis was conducted by univariate regression in a first step and, in case of significance, by multivariate regression additionally.
Results: Multivariate regression revealed an increased WMR ( < 0.001, OR (95%CI) 2.258 (1.460-3.492)), but also advanced age ( < 0.001, OR (95%CI) 1.050 (1.040-1.061)), increased CRP ( < 0.001, OR (95%CI) 1.010 (1.007-1.014)), and diabetes ( < 0.001, OR (95%CI) 2.386 (1.933-2.946)) as independent predictors for CLTI.
Conclusions: The WMR presents an easily obtainable and cost-effective parameter to identify LEAD patients at high risk for CLTI.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832925 | PMC |
http://dx.doi.org/10.3390/jcm8101593 | DOI Listing |
Pharmacotherapy
September 2025
Department of Biomedical Informatics, School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Background: Omeprazole, a widely used proton pump inhibitor, has been associated with rare but serious adverse events such as myopathy. Previous research suggests that concurrent use of omeprazole with fluconazole, a potent cytochrome P450 (CYP) 2C19/3A4 inhibitor, may increase the risk of myopathy. However, the contribution of genetic polymorphisms in CYP enzymes remains unclear.
View Article and Find Full Text PDFFood Funct
September 2025
School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
: The therapeutic potential of vegetarian diets in metabolic dysfunction-associated steatotic liver disease (MASLD) remains understudied in Asian populations. This randomized controlled trial aimed to evaluate the effects of a culturally adapted 6-month lacto-ovo-vegetarian diet (LOV-D) on hepatic steatosis and cardiometabolic risk factors through weight loss. : In this randomized trial, 220 Chinese adults with MASLD were assigned to LOV-D ( = 110) or an omnivore diet ( = 110) for 6 months.
View Article and Find Full Text PDFNeuro Oncol
September 2025
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Background: Disruption of the blood-brain barrier (BBB) in high-grade brain tumors is characterized by contrast accumulation on diagnostic imaging. This window of opportunity study correlates contrast imaging features with the tumor distribution of BBB-permeable (levetiracetam) and -impermeable (cefazolin) drugs.
Methods: Patients with a clinical diagnosis of a high-grade brain tumor underwent MRI for surgical planning.
Clin Transplant Res
September 2025
Division of Nephrology, Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Korea.
Background: Calcineurin inhibitor (CNI) toxicity is a significant cause of graft dysfunction in kidney transplant recipients, yet distinguishing it from acute rejection (AR) and acute tubular necrosis (ATN) remains challenging. This study investigated the use of urinary mRNA biomarkers as a noninvasive tool for identifying CNI toxicity.
Methods: We retrospectively enrolled 110 kidney transplant recipients and classified them into four groups based on pathological findings: stable graft function (n=35), CNI toxicity (n=25), AR (n=30), and ATN (n=20).
Gut Liver
September 2025
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
Background/aims: Despite medical advances in recent decades, the mortality rate of advanced liver cirrhosis remains high. Although liver transplantation remains the most effective treatment, candidate selection is limited by donor availability and alcohol abstinence requirements. Bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation has shown promise for the treatment of advanced cirrhosis.
View Article and Find Full Text PDF